Produced by AVE, it is a new serial of product with machine vision technology, low power screening, positioning, and high-power tracking recognition.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Excluding COVID-19 products, Group sales increase strongly by 8%1 at constant exchange rates (CER)

On the evening of July 26, Autobio announced that the company participated in the investment in Suzhou JinHe Fund as a limited partner, with a subscription amount of RMB 100 million.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended July 1, 2023.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Quest Diagnostics on Wednesday reported that its second quarter revenues fell 5 percent year over year although its base business revenues increased nearly 10 percent. The company also beat analysts' expectations on the top and bottom lines.

Medical device registration is an essential part of ensuring product safety, effectiveness, and quality. This article will introduce the whole process of medical device registration in detail, including pre-application preparation, registration test, clinical trial, establishment of system, application acceptance, approval of registration, issuance of registration certificate and follow-up supervision.

GE HealthCare raised its profit forecasts for 2023 after recording better-than-expected financials in its Q2 earnings report.

Danaher reported on Tuesday that its second quarter revenues fell approximately 8 percent year over year due to ongoing declines in COVID-related product demand and a drop in biotechnology business revenues.

Chinese IVD instruments market grows from RMB 10.12 billion to RMB 22.32 billion by 2020 from 2016 to 2020, at a CAGR of 21.9%. Stimulated by favorable national policies and the growing demand, it is expected to reach RMB 60.99 billion in 2025 and RMB 114.62 billion in 2030, growing at a CAGR of 22.3% and 13.4% during the periods 2020-2025 and 2025-2030, respectively.

DiaCarta said Monday that it has formed a strategic partnership with New Jersey-based contract research organization Hopkins MedTech Compliance/Hopkins MedTech Lab Services to provide validation and regulatory compliance services for laboratory test and in vitro diagnostic developers in the US.